Filing Flows › Neurocrine Biosciences (NBIX) › Q3 2026
Neurocrine Biosciences (NBIX) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 2, 2026
Neurocrine Biosciences (NBIX) reported revenue of $1.1B for the third quarter 2026 (Q3 2026), +41% from a year earlier and +17% from the quarter before. Operating margin was 29.5%, net earnings $206M (18.4% of revenue).
Neurocrine Biosciences, Q3 2026: revenue $1.1B (+41% year over year), operating margin 29.5%, net earnings $206M, operating cash flow $395M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.1B | +17% | +41% |
| Operating profit | $331M | +119% | +39% |
| Net earnings | $206M | +43% | -1% |
| Operating cash flow | $395M | +190% | +74% |
| Free cash flow | $384M | +198% | +79% |
What changed
Revenue was $1.1B in Q3 2026, up 41% year over year and up 17% from the previous quarter.
Operating profit was $0.33B, a 29.5% margin (down 0.6 points year over year). Of the extra revenue versus Q3 2025, 28% reached operating profit, below the 30% margin then. Total costs grew 42% against revenue growth of 41%. The fastest-growing cost line was Cost of revenue (+90%). Net earnings were $0.21B, down 1% year over year. The effective tax rate was 27.2%.
Operating cash flow was $0.40B (up 74% year over year), 191% of net earnings. Non-cash charges added back $0.04B of depreciation and amortization and $0.05B of share-based compensation. Working capital and other items added $0.09B. Capital expenditures of $0.01B left free cash flow of $0.38B.
Questions
What was Neurocrine Biosciences' revenue in the third quarter 2026?
Neurocrine Biosciences (NBIX) reported revenue of $1.1B for the third quarter 2026 (Q3 2026), +41% from a year earlier and +17% from the quarter before.
Was Neurocrine Biosciences profitable in the third quarter 2026?
Operating profit was $331M (29.5% of revenue) and net earnings $206M.